Sonar’s New, Powerful Deep-Analysis Capability Finds Hidden Code Level Security Issues
2.8.2023 16:00:00 EEST | Business Wire | Press release
Sonar, the leading Clean Code solution provider, today announced a significant advancement of its Clean Code offering – developers can now automatically discover and fix code security issues arising from interactions between user source code and third-party, open-source libraries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802497889/en/
Sonar deeper SAST finds hidden code level security issues (Graphic: Business Wire)
Referred to as deeper SAST, the new advanced detection addresses issues that traditional SAST tools miss by not following the flow within library code. Traditional SAST vendors analyze user application code. These tools do not scan the combined code, and flag libraries in an unsophisticated way, ignoring the context and use within the library. The result is that library features are considered black boxes, leaving organizations in the dark about whether they're truly secure for a given context or not. Moreover, these tools typically support only a handful of popular frameworks, often requiring up-front configurations for setup. All of this leads to the security issues created by the unique usage of third-party open source libraries going undetected.
“Code is code, whether it is written by a developer in your team or whether it comes as part of a library that is solving a specific problem. The two different approaches always bothered me, and I am thrilled that we are now able to analyze all codes the same way at once, solving what was considered an impossible problem,” said Olivier Gaudin, CEO and co-founder of Sonar. “With the deeper SAST advancements made to our Clean Code solution, organizations can discover these vulnerabilities and resolve them quickly as code is developed.”
Sonar addresses the gap of traditional SAST through its fine-grained analysis of user source code interactions with external dependencies, all without the need for any special configuration or incremental costs. This deeper SAST innovation furthers Sonar’s mission to equip organizations to achieve a state of Clean Code — code that is consistent, intentional, adaptable, and responsible. When code adheres to these characteristics, software becomes reliable, maintainable, and secure.
“It’s estimated that over 90% of applications leverage third-party libraries and interact with the code within them, but most SAST tools don’t tell developers which dependencies make their code vulnerable. Security is mission-critical, and the more issues you find and fix before they have the ability to cause you harm, the better off your business will be,” said Rik Turner, a Senior Principal Analyst covering cybersecurity at Omdia. “This is the essence of the proactive security wave we are seeing across the cyber sector: find it and fix it before it’s exploited.”
Sonar deeper SAST functionality is available at no additional cost within commercial editions of SonarQube (self-managed) and SonarCloud (cloud-based) — industry-leading static analysis code review tools that continuously inspect and analyze the codebase using quality gates to determine if code meets the defined standards for development and production. Deeper SAST currently supports Java, C#, and TypeScript programming languages and covers thousands of the topmost and commonly used open-source libraries, including their subsequent (transitive) dependencies.
Achieving a Clean Code State
Sonar empowers development teams to write Clean Code by providing them with the right tools and best practices, so they can spend less time fixing issues and more time meeting delivery and business goals. Pairing the Sonar solution with the company’s Clean as You Code methodology — set standards for keeping new, added, or edited code clean — and its educational guidance for code called ‘Learn as You Code,’ developers have faster issue remediation and delivery, code enhancement, and can further professional growth and team retention. Today, there are over seven million developers using Sonar.
Sonar also actively engages with its ecosystem and customer communities, in addition to partnerships with several universities for security research projects, and the open source software and start-up communities. Additionally, Sonar has a dedicated team of security researchers that find and responsibly disclose exploitable zero-day vulnerabilities in open-source software; these findings are used as inspiration for new security rules and detections to help find vulnerabilities.
Learn more about our deeper SAST innovation and Sonar solution (SonarQube, SonarCloud, SonarLint). Meet Sonar experts at Black Hat USA, booth #2760, August 8-10.
About Sonar
Sonar empowers developers and organizations to systematically achieve a state of Clean Code so that all code is fit for development and production. By applying the Sonar Clean as You Code methodology, organizations minimize risk, reduce technical debt, and derive more value from their software in a predictable and sustainable way.
The open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – supports over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering better software.
To learn more about Sonar, please visit https://www.sonarsource.com/company/about/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802497889/en/
Contact information
Katie Hyman
Senior PR Manager, Sonar
katie.hyman@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
